Farlow, M. R., & Lilly, M. L. (2005). Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BioMed Central.
Chicago Stili AlıntıFarlow, Martin R., ve Mary L. Lilly. Rivastigmine: An Open-label, Observational Study of Safety and Effectiveness in Treating Patients With Alzheimer's Disease for Up to 5 Years. BioMed Central, 2005.
MLA AlıntıFarlow, Martin R., ve Mary L. Lilly. Rivastigmine: An Open-label, Observational Study of Safety and Effectiveness in Treating Patients With Alzheimer's Disease for Up to 5 Years. BioMed Central, 2005.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..